Saturday 17 October 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 157.1%, free cash flow fell 351.4% and total debt rose 8.22%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

19.18 0.07 −0.36%

Follow AMRX

Alert me

Market cap: $6.2B
P/E: 38.4×
Fwd P/E: 51.6×
Dividend yield: —
F-score: 7/9
Altman Z: 1.94
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 9.82

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	—	—	—	—	1	—	—	3	—	—

Insider Ownership 55.00%

Capital & Financial Ratios $m

Market Cap 6,150.00

Revenue 3,117.55

Net Income 215.32

Free Cash Flow (11.59)

Net Debt 2,534.02

Current Ratio 2.20

Debt/Equity 80.86

P/E ratio 38.36

Fwd P/E 51.60

P/S ratio 1.96

P/B ratio 185.39

Past 5Y EPS Growth (18.45%)

This Y EPS Growth 23.35%

Next Y EPS Growth 16.44%

Next Y revenue growth 4.55%

Next 5Y EPS Growth 20.50%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 97.32%

10-year low 10-year high

P/B against its own 10 years 98.85%

10-year low 10-year high

EV/Sales against its own 10 years 93.27%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	99	118	311	136
Receivables	615	776	896	1,021
Inventory	581	612	606	678
Other	—	—	—	—
	1,378	1,588	1,911	1,947

	2023	2024	2025	Q'26
Payables	535	735	761	721
ST’ Debt	213	324	7	106
Other	77	32	43	18
	847	1,130	882	883

Compound Annual Growth %

	10y	5y	3y
Sales	13.37%	8.66%	10.92%
Cash Flow	13.91%	(2.15%)	73.50%
Earnings	2.31%	(4.57%)	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	723	796	—	—	—
’25	695	725	785	814	3,019
’24	659	702	702	731	2,794
’23	558	599	620	617	2,394
’22	498	559	546	610	2,212
’21	493	535	529	537	2,094
’20	499	465	519	510	1,993

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(27)	(21)	—	—	—
’25	7	84	118	130	340
’24	(4)	40	142	118	295
’23	140	(11)	81	136	346
’22	120	(126)	94	(23)	65
’21	148	(52)	82	63	242
’20	49	179	45	106	379

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(48)	(144)	—	—	—
’25	(10)	57	96	85	228
’24	(24)	28	121	95	220
’23	128	(24)	68	104	276
’22	108	(143)	(39)	49	(25)
’21	135	(61)	(3)	123	194
’20	41	(83)	30	326	313

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.19	0.18	—	—	—
’25	0.04	0.07	0.01	0.11	0.22
’24	(0.30)	0.02	0.00	(0.10)	(0.38)
’23	(0.05)	0.08	0.06	(0.56)	(0.48)
’22	(0.01)	(0.80)	(0.02)	(0.03)	(0.86)
’21	0.04	0.10	(0.04)	(0.04)	0.07
’20	0.78	(0.08)	(0.15)	(0.02)	0.61

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	12.80	2.27	2.40	3.89	1.95	1.24	5.01	6.69	Analyst estimates 2026–2028 Powerpack
	High	—	—	24.48	15.28	5.68	7.45	5.11	6.30	9.48	13.01
People
People	Employees	1,495	1,257	6,000	5,500	6,000	7,000	7,600	7,700	8,100	8,500
	Revenue/emp, $m	0.68	0.82	0.28	0.30	0.33	0.30	0.29	0.31	0.34	0.36
Income, $m
Income, $m	Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794	3,019
	Gross margin, %	58.68	50.90	43.08	21.70	31.54	36.73	35.47	34.28	36.52	36.88
	EBT	215	171	(203)	(220)	(36)	31	(248)	(40)	(55)	139
	EBT margin, %	21.10	16.57	(12.19)	(13.54)	(1.80)	1.50	(11.22)	(1.68)	(1.97)	4.61
	Net income	209	169	(201)	(604)	69	20	(255)	(49)	(74)	128
	Depreciation	36	51	154	250	244	243	249	241	265	246
Per share, $
Per share, $	Revenue	14.34	13.97	13.07	12.31	13.51	14.06	14.66	13.59	9.04	9.63
	Earnings	(6.63)	(6.53)	(1.58)	(2.74)	0.62	0.07	(0.86)	(0.48)	(0.38)	0.23
	Cash flow	1.62	3.16	1.97	0.01	2.57	1.62	0.43	1.96	0.96	1.09
	Capex	(1.75)	(1.54)	(0.56)	(0.74)	(0.45)	(0.32)	(0.60)	(0.39)	(0.24)	(0.36)
	Free cash flow	(0.13)	1.62	1.40	(0.72)	2.12	1.30	(0.17)	1.57	0.71	0.73
	Book value	8.79	(5.08)	7.04	2.63	2.34	2.46	1.22	0.11	(0.35)	(0.23)
	Shares, m	71	74	127	132	147	149	151	176	309	313
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	8.61	69.22	0.00	0.00	0.00	54.78
	P/S	0.96	0.96	1.04	0.39	0.34	0.34	0.14	0.44	0.88	1.31
	P/B	18.03	18.03	1.92	1.84	1.95	1.94	1.73	52.64	0.00	0.00
	EV/Sales	1.56	1.56	2.52	1.95	1.61	1.53	1.36	1.50	1.74	2.06
	EV/FCF	18.63	18.63	23.50	(33.18)	10.24	7.21	63.75	13.01	22.13	27.27
Cash, $m
Cash, $m	Operating cash flow	115	234	250	2	379	242	65	346	295	340
	Capex	(125)	(114)	(72)	(97)	(66)	(48)	(91)	(69)	(75)	(112)
	Free cash flow	(10)	120	178	(96)	313	194	(25)	276	220	228
Balance, $m
Balance, $m	Working capital	310	475	733	660	875	843	659	531	458	1,030
	Total debt	831	1,484	2,691	2,692	2,876	2,749	2,722	2,641	2,543	2,627
	Net debt	651	1,407	2,472	2,539	2,529	2,492	2,686	2,541	2,424	2,316
	Shareholders’ equity	624	(376)	896	347	345	367	184	20	(110)	(71)
Returns, %
Returns, %	ROA	0.00	0.00	(0.73)	(9.03)	2.37	0.27	(3.36)	(2.31)	(3.35)	2.01
	ROIC	13.96	14.86	(0.36)	(5.39)	1.98	3.34	(2.07)	4.99	6.73	10.97
	ROE	0.00	0.00	(8.03)	(58.23)	26.33	2.98	(47.19)	(82.35)	261.19	(79.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
AMLX Amylyx Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	−100.61% (below 0%: shrinking)	n/m	−24.50% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$6.4B	32.9×	24.8×	+13.58%	0.00%	+9.32%	72.03%	4.81%

All 86 Drug Manufacturers Specialty & Generic stocks →

AMNEAL PHARMACEUTICALS, INC. (AMRX) key facts

Strength: AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
AMNEAL PHARMACEUTICALS, INC. (AMRX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AMRX traded at $19.18, a market capitalization of $6.2 billion.
Return on equity was −79.7% and debt-to-equity 80.86.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.94 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.